Jaguar Health Executes Out-License Deal for Botanical Drug Candidate for Schizophrenia

Jaguar Health, Inc. (NASDAQ:JAGX) has announced an out-licensing agreement with Magdalena Biosciences, Inc. for the development of a botanical drug candidate aimed at treating schizophrenia. The candidate shows antipsychotic activity distinct from existing FDA-approved therapies.

Jaguar will receive 10% of upfront and milestone payments and royalties on sales if the drug receives FDA approval. The U.S. schizophrenia market, projected to reach $8.06 billion by 2030, presents significant commercial potential for the drug.

The joint venture between Jaguar and Filament Health Corp. focuses on developing plant-based prescription medicines. The botanical drug candidate may establish a new class of plant-based antipsychotic compounds.

Jaguar will present at the Lytham Partners Spring 2024 Investor Conference on May 30, 2024. Interested parties can register online to attend.